Marshall Wace’s Filana Therapeutics FLNA Stock Holding History

Marshall Wace’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.4M	Sell	2,012,543 -102,764	-5%	-$212K	﹤0.01%	1506
2025 Q4	$4.19M	Buy	2,115,307 +54,021	+3%	+$173K	﹤0.01%	1236
2025 Q3	$6M	Buy	2,061,286 +1,989,572	+2,774%	+$4.58M	0.01%	1120
2025 Q2	$130K	Buy	+71,714	New	+$128K	﹤0.01%	2514
2025 Q1	–	Sell	-21,093	Closed	-$49.8K	–	3035
2024 Q4	$49.8K	Buy	+21,093	New	+$370K	﹤0.01%	2487
2023 Q3	–	Sell	-24,348	Closed	-$597K	–	2618
2023 Q2	$597K	Buy	+24,348	New	+$586K	﹤0.01%	1921
2022 Q4	–	Sell	-157,325	Closed	-$6.58M	–	3359
2022 Q3	$6.58M	Buy	+157,325	New	+$4.25M	0.01%	1180
2021 Q2	–	Sell	-195,942	Closed	-$8.81M	–	3030
2021 Q1	$8.81M	Sell	195,942 -211,864	-52%	-$8.33M	0.04%	530
2020 Q4	$2.78M	Buy	407,806 +387,866	+1,945%	+$3.46M	0.02%	804
2020 Q3	$230K	Buy	+19,940	New	+$89.9K	﹤0.01%	1429
2020 Q1	–	Sell	-54,669	Closed	-$284K	–	2005
2019 Q4	$284K	Buy	+54,669	New	+$94.4K	﹤0.01%	1288

Other funds holding FLNA

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Marshall Wace's FLNA Position: Q1 2026 in Review

Marshall Wace reduced its Filana Therapeutics (FLNA) stake by 4.9% in Q1 2026, selling an estimated $212K and leaving 2,012,543 shares worth $3.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1506.

Marshall Wace first reported a position in FLNA in Q4 2019 and has held it in 11 quarters since. The position peaked at $8.81M in Q1 2021. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

Marshall Wace held 2,012,543 shares of Filana Therapeutics worth $3.4M as of Q1 2026.
Marshall Wace sold 102,764 Filana Therapeutics shares in Q1 2026, an estimated $212K.
Filana Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1506 holding.
Marshall Wace first reported a position in Filana Therapeutics in Q4 2019 and has held it in 11 quarters since.
Marshall Wace's Filana Therapeutics position peaked at $8.81M in Q1 2021.
101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.